AMD

After 10 years, AREDS2 formula shows increased efficacy compared to original formula, benefit of eliminating beta-carotene.

Study demonstrates results of pegcetacoplan as a geographic atrophy therapy.

According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.

After 10 years, AREDS2 formula shows increased efficacy compared to original formula, benefit of eliminating beta-carotene.

According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.

The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration.

Biogen and Samsung Bioepis announce the launch of ranibizumab-nuna and detail when the ophthalmic biosimilar will be available for retina specialists.

Faricimab is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

The company noted that pegcetacoplan, designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases, was granted Fast Track designation by the FDA for the treatment of geographic atrophy.

Outlook Therapeutics initially filed the BLA in March or the use of bevacizumab-vikg in the treatment of wet AMD. The company said it will re-submit a revised BLA by September.

The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration.

According to the company, the ReCLAIM-2 study of elamipretide demonstrates a correlation between ellipsoid zone dysfunction and vision.

Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

Alterations of the outer retinal layers from age-related macular degeneration (AMD) can interfere with the automated segmentation of the individual retinal layer thicknesses when using macular optical coherence tomography (OCT).

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.

Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.

As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.

A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.

The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.

Apellis revealed 18-month data for their investigational C3 therapy pegcetacoplan, unveiling continuous lesion growth reduction in eyes with geographic atrophy with monthly and every-other-month injections.

As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

The data presented at ARVO showed single subcutaneous doses of D-4517.2 were safe, well-tolerated in healthy subjects.

According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.